Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737516

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737516

Ambulatory Infusion Centers

PUBLISHED:
PAGES: 190 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Ambulatory Infusion Centers Market to Reach US$96.4 Billion by 2030

The global market for Ambulatory Infusion Centers estimated at US$50.9 Billion in the year 2024, is expected to reach US$96.4 Billion by 2030, growing at a CAGR of 11.3% over the analysis period 2024-2030. Blood Product Infusion, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$33.2 Billion by the end of the analysis period. Growth in the Iron Therapy segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.4 Billion While China is Forecast to Grow at 10.3% CAGR

The Ambulatory Infusion Centers market in the U.S. is estimated at US$13.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.8 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.1% and 9.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

Global Ambulatory Infusion Centers Market - Key Trends & Drivers Summarized

Why Are Ambulatory Infusion Centers Gaining Traction as a Patient-Centric Alternative to Hospital-Based Infusion Care?

Ambulatory infusion centers (AICs) are experiencing rapid global adoption as healthcare systems increasingly shift from inpatient to outpatient models to reduce costs, improve patient convenience, and alleviate hospital burdens. AICs offer infusion therapy in a non-acute setting for patients requiring biologics, specialty medications, or long-term intravenous treatments for chronic conditions such as autoimmune diseases, cancer, multiple sclerosis, and primary immunodeficiencies. Unlike hospital outpatient departments (HOPDs), AICs are typically standalone or clinic-based facilities that offer high-quality infusion care at a significantly lower cost, with shorter wait times and a more personalized treatment environment. This care model aligns with payer priorities, particularly in the U.S., where commercial insurers and Medicare Advantage plans are increasingly steering patients away from high-cost hospital infusions.

The rising prevalence of chronic and complex diseases requiring regular infusion therapy is amplifying the need for scalable, decentralized treatment solutions. Patients prefer AICs for their accessibility, streamlined scheduling, and lower exposure to nosocomial infections-a key consideration for immunocompromised populations. Furthermore, advancements in specialty drug development, particularly in oncology, rheumatology, and neurology, are creating a steady pipeline of infused therapies that must be administered in clinically controlled but cost-optimized settings. AICs are emerging as the ideal intersection of safety, efficacy, and efficiency, offering flexible scheduling, closer-to-home care, and coordinated case management-all critical factors in improving treatment adherence and long-term outcomes.

How Are Reimbursement Trends and Clinical Innovations Reshaping the AIC Business Model?

Evolving reimbursement structures and value-based care mandates are significantly influencing the expansion of ambulatory infusion centers. In several markets, payer policies are being recalibrated to favor site-of-care optimization, with reimbursement rates for HOPDs increasingly scrutinized for high overhead costs. As a result, AICs-which typically operate at 40% to 60% lower cost per infusion-are gaining preference among insurers, who are encouraging site shifts through benefit design, patient education, and network contracts. The availability of biosimilars is also reshaping infusion economics, enabling AICs to offer competitive pricing while maintaining strong margins on high-volume therapeutics such as infliximab, rituximab, and trastuzumab. These shifts are reinforcing the viability of independent infusion center models and sparking interest from physician groups, health systems, and private equity investors seeking to scale outpatient infusion networks.

Technological integration is also transforming AIC operations. Electronic health records (EHRs) tailored for infusion workflows, smart infusion pumps with safety alerts, and real-time scheduling systems are improving care coordination and clinical safety. Clinical protocols are being standardized to ensure consistency in drug preparation, dosing, and monitoring, while nurse training programs are being expanded to meet demand for infusion-certified personnel. Some AICs are incorporating telehealth consults, remote patient monitoring, and integrated care pathways with specialists to enhance continuity of care. Moreover, data analytics and population health tools are being used to track patient outcomes and optimize therapy regimens, supporting the transition to outcomes-based reimbursement. These innovations are elevating the role of AICs from basic procedural centers to integrated chronic disease management hubs.

Where Is Demand Accelerating and Which Therapeutic Areas Are Driving Volume?

Demand for ambulatory infusion centers is accelerating in both urban and suburban regions across North America, Western Europe, and selected parts of Asia-Pacific where outpatient infrastructure is evolving in line with chronic disease prevalence. The U.S. is the most mature market, with thousands of AICs now operating as part of multi-specialty practices, independent networks, and integrated health systems. Insurer-backed infusion benefit management is accelerating patient migration from hospitals to AICs, especially for high-volume biologic therapies used in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. In Europe, rising pressure to reduce healthcare expenditures is pushing governments to explore outpatient infusion delivery models, particularly for oncology and hematology care. Countries such as Germany, the U.K., and the Netherlands are investing in community-based infusion networks and home infusion pilots.

Therapeutic areas driving infusion center volume include immunology, neurology, oncology, and infectious diseases. Monoclonal antibody therapies, intravenous immunoglobulin (IVIG), and iron infusions are among the highest-volume services. The oncology sector is seeing increased AIC adoption for maintenance chemotherapy, immunotherapy, and supportive care infusions such as antiemetics and hydration therapy. In neurology, diseases such as multiple sclerosis and myasthenia gravis are requiring routine infusions of natalizumab and eculizumab, respectively, often delivered in AICs to improve access and minimize travel burden. The COVID-19 pandemic has further spotlighted the role of AICs in emergency therapeutics, with monoclonal antibody treatments and antiviral IV therapies administered in outpatient settings to relieve hospital load. As new infused therapies are launched across rare disease and specialty indications, AICs are poised to become the default channel for cost-effective, high-frequency outpatient infusion delivery.

What Is Fueling the Growth of the Ambulatory Infusion Centers Market Globally?

The growth in the ambulatory infusion centers market is driven by several factors, including rising demand for specialty biologics, payer pressure to shift infusion care to lower-cost settings, and evolving patient expectations for convenience and personalized care. One of the primary growth drivers is the expanding pipeline of complex, infused therapeutics requiring ongoing administration outside the hospital environment. As drug manufacturers bring to market new monoclonal antibodies, gene therapies, and long-acting injectables, the need for safe, scalable infusion infrastructure continues to climb. AICs offer a platform to deliver these therapies under controlled, nurse-supervised conditions while supporting high patient throughput and minimal infrastructure overhead.

Reimbursement optimization, alongside cost transparency, is further strengthening AIC adoption. Insurers are actively directing patients to ambulatory settings through site-of-care steering programs, helping reduce infusion therapy costs by thousands of dollars per session. Additionally, rising venture capital and health system investments are fueling geographic expansion, standardization, and operational integration of AIC networks. Demographic trends-particularly aging populations and the growing prevalence of chronic autoimmune, neurologic, and oncologic conditions-are expanding the long-term demand base. Innovations in care coordination, digital health integration, and patient engagement are enabling AICs to offer comprehensive, longitudinal infusion support. These intersecting clinical, financial, and demographic dynamics are accelerating market expansion-raising the question: Will ambulatory infusion centers become the global standard for administering complex biologics and chronic infusion therapies in a decentralized healthcare future?

SCOPE OF STUDY:

The report analyzes the Ambulatory Infusion Centers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy, Other Therapy Types); Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications); End-User (Hospitals, Specialty Clinics, Homecare Settings, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Amedisys, Inc.
  • AmerisourceBergen Corporation
  • Arnot Health
  • Baxter International Inc.
  • Cedars-Sinai
  • CHI Health at Home
  • ChristianaCare
  • CitusHealth
  • Cleveland Clinic
  • Coram CVS Specialty Infusion Services
  • CVS Health
  • FlexCare Infusion Centers
  • Fresenius Kabi
  • Hawaii Medical Service Association
  • Healix, LLC
  • InfuCare Rx
  • InfuSystem Holdings, Inc.
  • IVX Health
  • KabaFusion
  • McKesson Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33442

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Ambulatory Infusion Centers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Cost-Efficient Care Settings Drives Utilization of Ambulatory Infusion Centers
    • Expanding Use of Biologics and Specialty Therapies Boosts Demand for Ambulatory Infusion Centers
    • Patient Preference for Convenience and Shorter Visits Encourages Adoption of Ambulatory Infusion Centers
    • Technological Improvements in Infusion Equipment Enhance Operational Efficiency at Ambulatory Infusion Centers
    • Rising Burden of Chronic Illnesses Increases Reliance on Ambulatory Infusion Centers for Ongoing Care
    • Integration of Electronic Health Records Strengthens Clinical Capabilities of Ambulatory Infusion Centers
    • Retail and Standalone Infusion Clinics Expand Market Reach of Ambulatory Infusion Centers
    • Favorable Reimbursement Policies Support Continued Expansion of Ambulatory Infusion Centers
    • Emergence of Hybrid Home-and-Center Models Increases Versatility of Ambulatory Infusion Centers
    • Infection Control Protocols Improve Patient Confidence in Ambulatory Infusion Centers
    • Strategic Growth by Physician Groups and Pharmacy Chains Enhances Availability of Ambulatory Infusion Centers
    • Chronic Disease Management Trends Position Ambulatory Infusion Centers as Critical Healthcare Infrastructure
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ambulatory Infusion Centers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Ambulatory Infusion Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Blood Product Infusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Blood Product Infusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Iron Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Iron Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Steroid Infusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Steroid Infusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Immunoglobulin Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Therapeutic Phlebotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Therapeutic Phlebotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Plasmapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Plasmapheresis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clotting Factor Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Clotting Factor Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Bone Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Bone Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Diabetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Diabetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • JAPAN
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • CHINA
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • EUROPE
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Ambulatory Infusion Centers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • FRANCE
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • GERMANY
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • ITALY
    • TABLE 82: Italy Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Italy 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • UNITED KINGDOM
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 88: UK Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: UK 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 90: UK Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: UK 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 106: Rest of World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of World 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 108: Rest of World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of World 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of World 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!